A study of Ev.FV on wound healing in dystrophic epidermolysis bullosa
Part of Genetic & congenital, Skin clinical trials.
This trial tests if a drug called Ev.FV can help heal wounds in people with dystrophic epidermolysis bullosa (DEB), a condition that causes fragile, blistering skin. It is for people with open wounds on their arms, legs, or trunk that are a specific size.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have been diagnosed with dystrophic epidermolysis bullosa (DEB), either the severe or milder form.
- You must have at least one active wound on your arms, legs, or trunk that is between 10 and 50 square centimeters in size (about the size of a small to large bandage).
- You must be willing to follow the study rules and give your consent to participate.
- You must test negative for drugs in a urine test at the screening visit.
- You must not have a serious infection, a history of bone marrow transplant, an autoimmune disease (like insulin-dependent diabetes), or a severe medical condition like cancer that limits your ability to come to the clinic.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This early-stage study tests stem cell–derived “extra-cellular vesicles” (small natural cell packages) to help heal painful skin wounds in people with dystrophic epidermolysis bullosa (DEB). If you have suitable, untreated wounds and meet the safety requirements, you may be able to join and help researchers learn whether this treatment is beneficial.
This study tests an investigational drug called efgartigimod, which may help reduce harmful antibodies that attack the skin in certain blistering diseases. It is designed for people with dystrophic epidermolysis bullosa (DEB) or epidermolysis bullosa acquisita (EBA) who have antibodies against collagen VII.
This trial tests a new cream that may help heal wounds in people with epidermolysis bullosa (EB), a condition causing fragile skin that blisters easily. The cream is applied directly to the wounds, and researchers will compare two similar wounds on the same person to see if the cream works better than a cream without the medicine.
This trial tests if intravenous immunoglobulin (IV IgG) can help people with a form of epidermolysis bullosa who have antibodies against collagen VII. It may reduce blistering and improve wound healing.
This trial tests a gel called TCP-25 on wounds caused by a specific type of epidermolysis bullosa (DEB or JEB). It aims to see if the gel can help heal wounds and improve comfort.
This study tests an experimental eye drop (KB803) to see if it can reduce painful scrapes on the surface of the eye in people with dystrophic epidermolysis bullosa. You would be randomly assigned to receive either the study drops or a placebo (an inactive drop) for several months.
Hear when a new Dystrophic Epidermolysis Bullosa trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.